polycystic ovarian syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: oral intake of oligopin (50mg capsule) after lunch, once a day for 12 weeks. Intervention 2: Control group: oral intake of placebo after lunch, once a day for 12 we
Sponsors
Alborz University of Medical Sciences
Endocrinology and Metabolism Research Institute
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: PCOS diagnosis according to Androgen Excess Society criteria: hyperandrogenism (hirsutism) / hyperandrogenemia (testosterone >70ng/dl) and/or oligomenorrhea (<8 spontaneous menses per year) and/or polycystic ovarian morphology on ultrasound Women aged from 18 to 40 years old Normal prolactin normal thyroid function 17-OH progesterone No evidence of Androgenic hormone secretory tumors No Cushing's syndrome or acromegaly
Exclusion criteria
Exclusion criteria: Using either oral contraceptives or steroids hormones during 1 month before the onset of the trial Using medications that could modify the metabolism during 1 month before the onset of the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| S.H.B.G) Sex Hormon Binding Globolin). Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;FSH. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;LH. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;Fasting blood sugar. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;Testosterone. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;DHEA-S. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| HDL-C. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;LDL-C. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;Total cholesterol. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;TG. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;Cr. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;Hs-CRP. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;HbA1C. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;Insulin. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test.;Prolactin. Timepoint: Before and 12 weeks after the intervention. Method of measurement: ng/mL.;TSH. Timepoint: Before and 12 weeks after the intervention. Method of measurement: blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Hosseini
Endocrinology and Metabolism Research Institute
Outcome results
None listed